Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment

L. Priano, G. Albani, A. Brioschi, G. Guastamacchia, S. Calderoni, L. Lopiano, M. Rizzone, R. Cavalli, M. R. Gasco, F. Fraschini, B. Bergamasco, A. Mauro

Research output: Contribution to journalArticlepeer-review

Abstract

This study analyzed the macrostructure and microstructure of sleep in 12 parkinsonian patients under basal conditions (T0) and during 1-night treatment (T1) with a new formulation of apomorphine. This new formulation consisted in a microemulsion of apomorphine administered by the transdermal route, able to provide a constant release of the drug over several hours (APO-TD). Sleep analysis at T1 compared with T0 revealed a 16% increment of total sleep time, a 12% increment of sleep efficiency, a 16% increment of stage 3 and 4 non-REM sleep, a 15% reduction of periodic limb movements index, a 22% reduction of arousal index, and a 23% reduction of cycling alternating patterns/non-REM. We conclude that APO-TD may be able to reduce nocturnal anomalous movements, akinesia, and rigidity in Parkinson's disease, and may reduce the disturbed sleep typical of Parkinson's disease.

Original languageEnglish
Pages (from-to)207-208
Number of pages2
JournalNeurological Sciences
Volume24
Issue number3
DOIs
Publication statusPublished - Oct 2003

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment'. Together they form a unique fingerprint.

Cite this